RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Several mechanisms and cell types are involved in the regulation of the immune response.
These include mostly regulatory T cells (Tregs), regulatory macrophages (Mregs), myeloid …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …

Skin cutaneous melanoma (SKCM, hereafter referred to as melanoma) is the most lethal
skin cancer with increasing incidence. Regulated cell death plays an important role in …